Related Experiment Video
Updated: Jun 17, 2025
05:12
Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
Published on: June 23, 2023
883
Alcohol consumption and heart failure: a dose-response meta-analysis
Bethany Wong1,2, Cristin Ryan3, Adeniyi Fagbamigbe4,5
1School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
The Cochrane Database of Systematic Reviews
|August 9, 2024
Summary
This review examines how alcohol consumption impacts heart failure progression in at-risk individuals. It assesses alcohol
Area of Science:
- Cardiology and Cardiovascular Health
- Public Health and Preventative Medicine
- Alcohol-Related Research
Background:
- Heart failure is a significant global health concern.
- Identifying modifiable risk factors like alcohol consumption is crucial for prevention.
- Early stages of heart failure (Stage A and B) offer opportunities for intervention.
Purpose of the Study:
- To evaluate the impact of alcohol consumption on the progression to symptomatic heart failure (Stage C).
- To assess alcohol's effect on left ventricular dysfunction in early-stage heart failure.
- To investigate alcohol's role in the development of different heart failure types (HFrEF, HFmrEF, HFpEF).
Main Methods:
- This study outlines a protocol for a Cochrane Review.
- Systematic review methodology will be employed to synthesize existing evidence.
- The review will focus on individuals at risk for or in the early stages of heart failure.
Main Results:
- This section is not applicable as the output is a protocol.
- Results will be determined upon completion of the systematic review.
- The review aims to quantify the association between alcohol intake and heart failure development.
Conclusions:
- Understanding alcohol's influence on heart failure progression is vital for clinical guidelines.
- Evidence-based recommendations can be developed to mitigate alcohol-related cardiovascular risks.
- This review will provide clarity on alcohol consumption's role in heart failure development.
More Related Videos
05:40The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans
Published on: April 28, 2022
3.0K
07:31Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
7.9K
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
01:22Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
01:22Heart Failure Drugs: β-Blockers
326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
01:11Renal Failure: Dose Adjustments
77
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77